Navigation Links
AMRI Announces Appointment of William Marth as Chairman of the Board of Directors
Date:6/5/2013

ALBANY, N.Y., June 5, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI), a leading global contract research and manufacturing organization, has announced that the Board of Directors has unanimously voted to separate the role of Chairman and Chief Executive Officer and has named William S. Marth , an active member of the AMRI Board of Directors, as Chairman of the Board, effective June 5, 2013. The position of Chairman has been held by Thomas E. D'Ambra, Ph.D. since the Company's founding.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

Dr. D'Ambra retains his roles as a member of the Board of Directors, President and CEO. Mr. Marth was appointed to the AMRI Board of Directors in 2012, joining Veronica G. H. Jordan , Ph.D.; Gabriel Leung ; Kevin O'Connor ; Arthur J. Roth ; and Una S. Ryan , O.B.E., Ph.D.

Mr. Marth said, "AMRI maintains a unique and strong position providing a broad range of drug discovery, development and manufacturing services to the pharmaceutical, biotechnology and related industries. I have been impressed with the Company's accomplishments and potential and look forward to contributing to growing both the depth and breadth of AMRI's services in my role as Chairman."

Dr. D'Ambra said, "Bill is an accomplished and visionary industry leader who has an unparalleled record of commercial success. Since joining the Board approximately one year ago, he has been very helpful to me personally as well as to the Company. I am confident with Bill as our Chairman, that the Company is poised for continued and greater success. I, along with the rest of the members of the Board of Directors, look forward to continuing to serve with Bill on behalf of all AMRI shareholders. AMRI's success has been built on a reputation for the highest quality standards in its work and ethics. Our corporate governance structure demonstrates AMRI's commitment to sustaining a superior level of performance."

Mr. Marth, formerly President and Chief Executive Officer of Teva – Americas, retired from Teva in 2012. He had previously served as President and Chief Executive Officer of Teva North America from January 2008 to June 2010 and prior to that as President and Chief Executive Officer of Teva USA. He was previously Executive Vice President and Vice President of Sales and Marketing for Teva USA.

Mr. Marth played a significant role in establishing Teva as a leading Specialty Pharmaceutical company and being ultimately recognized as the worldwide No. 1 producer of generic drugs. In his role, he led respiratory, neuroscience, oncology and women's healthcare divisions, as well as Latin America and Canada. He was a member of Teva's global executive management team and Teva Americas' board of directors since 2007. He brings to this role his global experience in Strategic Planning, IR, R&D, Supply Chain and Regulatory. He was the architect of the $6.8 billion Cephalon and $7.4 billion Barr Laboratories acquisitions. Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol-Myers Squibb.

Mr. Marth, who earned his B.Sc. in Pharmacy from the University of Illinois in 1977 and his M.B.A. in 1989 from the Keller Graduate School of Management, DeVry University, is a licensed pharmacist and serves on various other boards and committees, including The University of the Sciences in Philadelphia and the Board of Ambassadors for John Hopkins' Project RESTORE. In addition, Mr. Marth served as the Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2008 and 2009 and the American Society for Health-System Pharmacists (ASHP) in 2010.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).


'/>"/>
SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bernstein Liebhard LLP Announces That a Class Action Has Been Filed Against Intuitive Surgical, Inc.
2. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Invacare Corporation
3. Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients
4. Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis
5. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
6. SI-BONE, Inc. Announces Publication of Postmarket Surveillance Safety Data on First 5,319 Patients Treated with iFuse Implant System
7. Pressure BioSciences Announces Core Technology Breakthrough
8. MGT Capital Investments, Inc. Announces Sale of Medicsight Patents
9. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
10. Cheetah Medical Announces New Management Team
11. Accelerate Diagnostics Announces Plans For Rights Offering To Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
(Date:7/26/2017)... SINGAPORE , July 27, 2017  Radium Medical Aesthetics, a ... LASEMD, designed to delay aging by effectively addressing several skin conditions ... the skin to become rougher and more fragile. The skin becomes ... the unavoidable exposure to the harmful UV rays from the sun ... hyperpigmentation. ...
(Date:7/26/2017)... , July 26, 2017 The Galien ... Prix Galien USA Award Nominees. Counted ... Prix Galien Award recognizes outstanding biomedical and technology product achievement ... To qualify, each candidate must be U.S. Food ... five years and demonstrate tremendous potential to impact human health. ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 2017 , ... Hernandez Insurance Agencies, a northern Virginia firm ... DC region, is inaugurating a “New Leash On Life” charity initiative in conjunction ... to be companions for veterans in need. , The Semper K9 organization works ...
(Date:8/18/2017)... ... , ... The Brian Gifford Agency, an Indiana-based firm providing asset protection and ... Academy in a charity drive to provide for at-risk children and teens in the ... is a nonprofit organization that has offered critical programs to at-risk and foster children ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 ... bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for people ... such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in ...
(Date:8/18/2017)... Vermont (PRWEB) , ... August 18, 2017 , ... ... phone numbers and call tracking and monitoring solutions, announced today the launch of ... site include a modern navigation and aesthetic, fully responsive design, and an enhanced ...
(Date:8/18/2017)... ... 18, 2017 , ... “Beyond Our Imaginations: The Infinite God”: shows the importance ... God” is the creation of published author, Mark Lawrence, born in Michigan, the author ... problem with becoming a greater man of God is that I have to be ...
Breaking Medicine News(10 mins):